Multi-dimensional MRI habitat mapping to predict key gene mutations and prognosis in high-grade gliomas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multi-center observational project combines a retrospective and a prospective arm to link multi-dimensional MRI heterogeneity features with molecular markers and patient outcomes in WHO grade III–IV gliomas. Retrospective cases with preoperative contrast MRI and available molecular testing will be analyzed to identify imaging features that correlate with mutations such as IDH, MGMT, 1p/19q, TERT, CDKN2A/B and BRAF. Prospectively, patients with suspected high-grade gliomas will undergo a standardized ~40-minute MRI protocol and clinical follow-up to test if the imaging-derived habitats predict prognosis. The approach leverages noninvasive spatial 'habitat' mapping to capture intratumoral heterogeneity across the whole tumor rather than single-point sampling.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Retrospective Study:

1. Participants aged 18 to 70 years, of any gender.
2. Confirmed postoperative pathology of adult diffuse glioma (WHO Grade III-IV).
3. Standard MR contrast-enhanced imaging performed within 10 days before surgery.
4. No history of prior radiotherapy or chemotherapy before surgery.
5. Absence of concurrent significant comorbidities or other tumors.
6. Presence of molecular testing results (including IDH, MGMT, 1p19q, TERT, CDKN2A/B, BRAF).
7. Availability of comprehensive clinical and follow-up data.

Prospective Study:

1. Participants aged 18 to 70 years, of any gender.
2. Clinically suspected to have high-grade gliomas preoperatively, with final pathology confirming high-grade gliomas.
3. Stable vital signs and capable of cooperating for a 40-minute MR scan.
4. Absence of significant underlying medical conditions or history of other tumors.
5. Documentation of informed consent through a signed consent form.

Exclusion Criteria:

Retrospective Study:

1. MRI images with artifacts or presence of intratumoral hemorrhage.
2. Incomplete clinical data available.

Prospective Study:

1. Individuals with claustrophobia or other reasons unable to undergo MRI scans.
2. History of allergic reactions to MRI contrast agents.
3. Inappropriate for prolonged MRI scans due to other reasons.

Where it's running

• Department of Radiology, Renji Hospital School of Medicine, Shanghai Jiao Tong University
  Shanghai, Select A State Or Province, China Recruiting
• Department of Radiology, Renji hospital, School of Medicine, Shanghai Jiao Tong University
  Shanghai, Shanghai Municipality, China Active not recruiting

Study contacts

• Study coordinator: Yan Zhou, MD,PhD
• Email: clare1475@hotmail.com
• Phone: +86-021-68383086

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Taste of hope: testing NRG-103 safety and dosing for adults with high-grade glioma

  This early-phase trial tests whether NRG-103 is safe and tolerable in adults with recurrent or progressive high-grade glioma and looks for early signs it might help.

  Recruiting at 2 sites Phase 1 Neuregen Therapeutics Co., Ltd. · Shanghai and 2 other locations · NCT07710690

• Dual-target CAR-NK cell therapy for recurrent glioblastoma and high-grade glioma

  This phase 1 study will test whether injecting dual-target CAR-NK cells into the brain is safe and can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07480941

• Intratumoral DNX-2401 for High-Grade Pediatric Brain Tumors

  This study tests whether a single injection of DNX-2401 into a pediatric brain tumor can help shrink the tumor and extend survival in kids and young adults with recurrent or refractory high-grade brain tumors.

  Recruiting Phase 2 Clinica Universidad de Navarra, Universidad de Navarra · Utrecht and 1 other locations · NCT07424092

• LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma

  This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07416188

• Fluorescence-enhanced stereotactic biopsy needle for tumor and vessel detection

  This project will test a biopsy needle fitted with 5-ALA fluorescence, Raman spectroscopy, and ultrasound to see if it can identify tumor tissue and blood vessels in adults with high-grade glioma.

  Recruiting Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Milan · NCT07286903

• Fluorescent-labeled nivolumab (Nivo800) imaging for high-grade glioma surgery

  This trial tests whether a near-infrared fluorescent version of the immunotherapy drug nivolumab can be given before planned surgery to visualize drug distribution in adults with suspected high-grade glioma.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07210632

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.